Nemaura Medical (NASDAQ:NMRD) is a medical technology company focused on the development and commercialization of non-invasive diagnostic and monitoring solutions for chronic health conditions. Headquartered in the United Kingdom with operations in the United States, Nemaura’s flagship offering is SugarBEAT, a wearable, disposable patch that continuously monitors glucose levels for individuals with diabetes without the need for finger-prick blood samples. The company leverages proprietary sensor technology to provide real-time data that can be accessed via a dedicated mobile application, delivering insights to both patients and healthcare providers.
The core business activity of Nemaura Medical centers on research, development and regulatory approval of its patented adhesive sensor patches. SugarBEAT received CE Mark approval in Europe and has undergone clinical trials to validate its accuracy and performance against established glucose monitoring methods. In addition to glucose monitoring, the company is exploring the broader application of its sensor platform to measure other biomarkers, positioning itself at the intersection of wearable technology, digital health and personalized medicine.
Nemaura Medical serves markets in Europe, North America and select Asia-Pacific regions, working through partnerships with distributors, healthcare institutions and telehealth providers. By integrating its sensor data with cloud-based analytics and machine learning algorithms, the company aims to enhance chronic disease management, improve patient adherence, and facilitate remote monitoring. Strategic collaborations with endocrinologists, diabetes clinics and health systems are a key part of Nemaura’s go-to-market strategy.
Founded over a decade ago by serial entrepreneur Dr. Faz Chowdhury, Nemaura Medical is led by a management team with extensive experience in medical devices, regulatory affairs and digital health. The board includes industry veterans from leading pharmaceutical and diagnostics firms, underscoring the company’s commitment to rigorous clinical standards and scalable commercialization. With a focus on minimally invasive monitoring solutions, Nemaura continues to advance its pipeline and expand global reach to address the growing burden of chronic diseases worldwide.
